Unichem Final Project Report

Introduction to Organization Study

Introduction: This is an overall study of the organization of Unichem laboratory Ltd. where it’s working environment and various policies and practice are studied

OBJECTIVES OF THE STUDY:

1. To fami familia liarize rize with with a busine business ss organi organizati zation on 2.

To fam familiariz arizee with the dif differ ferent depar partments in the org organi anization tion and their functioning.

3.

To enab enable le to unde underrstan stand d how how the the key key busi busine ness ss proc proces esss are are carr carrie ied d out out in organizations.

4.

Unde Unders rsta tand nd how how info inform rmat atio ion n is used used in orga organi niza zati tion on for for deci decisi sion on maki making ng at various levels.

5. To know know the histo history ry about about the company company.. 6. To get clear clear cut idea idea about about the manage managemen mentt and administ administrati ration. on. 7. To know know about about the indust industrial rial relat relation ion in the the company company.. 8. To analyze analyze the strength strength and weaknes weakness. s. 9. To get clear clear cut idea idea about about the variou variouss departme departments nts and funct functions ions.. 10. To give findings findings and solutions. solutions. 11. To relate relate theory with with practice. practice.

City College

1

Dept. of Management Studies

Trusted by over 1 million members

Try Scribd FREE for 30 days to access over 125 million titles without ads or interruptions! Start Free Trial Cancel Anytime.













INDUSTRY PROFILE

The Indian pharmaceutical pharmaceutical industry is one of the developing world’s largest and most developed, ranking 4th in the world in terms of production volume and 13th in domest domestic ic consu consump mpti tion on value. value. India India’s ’s indus industr try, y, value valued d at $5.3 $5.3 bill billion ion in 200 2005, 5, represents less than one percent of the global pharmaceutical industry ($550 billion). Over the last 30 years, India’s pharmaceutical industry has evolved from almost nonexistent to a world leader in the production of high quality generic drugs. India has garnered a worldwide reputation for producing high quality, low cost generic drugs. The industry currently meets India’s demand for bulk drugs and nearly all its demand demand for formula formulation tions, s, with with the remain remainder der supplied supplied by foreign foreign multina multination tional al corporations (MNCs). India’s pharmaceutical industry is one of the fastest growing segments of the Indian economy with an average annual growth rate of 14 percent during 2002-2005. Overall, the Indian market for pharmaceuticals is projected to grow at an average annual rate of between 15 and 20 percent during 2005-2010. The surge in production has been driven by legislative reforms, the growth in contract manufacturing and outsourcing, value added foreign acquisitions and joint ventures, India’s mastery of reverse engineering of patented drug molecules, and India’s efforts to comply comply with with its World World Trade Trade Organiz Organizatio ation n (WTO) (WTO) Trade Trade Relate Related d Intellec Intellectual tual Prop Proper erty ty Agre Agreem emen entt

obli obliga gati tion ons. s. When When Indi Indiaa join joined ed the the WTO WTO in 1995 1995,, its its

pharmaceutical exports were valued at less than $600 million. By 2005, its exports had grown grown to $3.7 $3.7 billi billion on and account accounted ed for more than than 61 percen percentt of indus industr try y turnover. Currently, Indian pharmaceutical companies produce between 20 and 22 perc percent ent of the worl world’s d’s gener generic ic drugs drugs (in (in value value terms terms)) and offer offer 60,000 60,000 finis finished hed medicines and nearly 400 bulk drugs used in formulations.4 With changes in India’s patent laws in the early 1970s, Indian drug producers became experts in ‘reverse engineering’ and increased its supply of less expensive copies of the world’s bestselling patent protected drugs. India’s pharmaceutical pharmaceutical industry grew and prospered in a highly highly regulat regulated ed environm environment ent with with governm government ent price price control controlss on a signifi significant cant number of formulations and bulk drugs. In January 2005, India amended its patent















manufacture and market reverse-engineered versions of drugs patented by foreign drug producers. To replace sales lost to TRIPs compliance, many of India’s leading pharmaceutical pharmaceutical producers have increased their exports of generic drugs to the United States and Western Europe and entered into research and development agreements, mergers and acquisitions, and other alliances with foreign pharmaceutical firms.

India’s Pharmaceutical industry: Independence to 2005

At the time of independence in 1947, India’s pharmaceutical market was dominated by Western MNCs that controlled between 80 and 90 percent of the market primarily through importation. Approximately 99 percent of all pharmaceutical products under patent in India at the time were held by foreign companies and domestic Indian drug prices prices were were among among the highest in the world. world. The Indian pharmac pharmaceuti eutical cal market market remained remained import-dependent import-dependent through the 1960s until the government government initiated policies stressing self-reliance through local production.5 At that time, 8 of India’s top 10 pharmaceutical firms, based on sales, were subsidiaries of MNCs. To facilitate an inde indepe pend nden entt supp supply ly of phar pharma mace ceut utic ical al prod produc ucts ts in the the dome domest stic ic mark market et,, the the government of India founded 5 state-owned pharmaceutical companies.6 Today, India is the world’s fifth largest producer of bulk drugs. Government policy culminated in various actions including: the abolition of product patents on food, chemicals, and drugs; the institution of process patents; the limitation of multinational equity share in India India pharmac pharmaceuti eutical cal compani companies, es, and the imposit imposition ion of price price control controlss on certain certain form formul ulat atio ions ns

and and

bulk bulk

drug drugs. s.

Subs Subseq eque uent ntly ly,,

most most

fore foreig ign n

phar pharma mace ceut utic ical al

manufacturers abandoned the Indian market due to the absence of legal mechanisms to protect their patented products. Accordingly, the share of the domestic Indian market held by foreign drug manufacturers declined to less than 20 percent in 2005. As the MNCs abandoned the Indian market, local firms firms rushed in to fill the void, and by 1990, India was self-sufficient in the production of formulations and nearly selfsufficient in the production of bulk drugs.

Strengths and weaknesses of India’s pharmaceutical industry:

India’s comparative advantages lie in its cost competitiveness, its reverse engineering















India produces some of the cheapest drugs in the world, especially because labor costs are 50 to 55 percent cheaper than in the West.50 Industry experts indicate that infrastructure infrastructure costs are 40 percent lower and fixed cost are estimated to be 12 percent to 20 percent less that in the United States and Western Europe. Consequently, India can produce bulk drugs that cost 60 percent less that in the West and can open a production plant in India 40 percent cheaper than in developed countries. Because of this, this, India India has becom becomee a hub for pharm pharmac aceut eutic ical al resear research ch and develo developm pment ent and clinical trials for many leading foreign pharmaceutical companies.















COMPANY PROFILE

Introduction: In Himachal Pradesh, the 'Dev Bhumi' or the land of the gods, renowned in India for its mythological nexus and beautiful landscapes, is situated an upcoming industrial township - Baddi.

Baddi is located about 45 kms from the architectural architectural paradigm, Chandigarh, Chandigarh, the town is surrounded by lush green hills of the Shivalik range of mountains. In the far end of the town, at the foothills, you come across a structure, which nestles in its ambiance, a visual visual delight delight.. This This is the state-o state-of-th f-the-ar e-artt pharmac pharmaceuti eutical cal manufac manufacturi turing ng unit of Unichem Laboratories Limited, merging aptly into its backdrop, yet starkly standing alone in its individuality.

Thee Worl Th World d class class Baddi Baddi plant plant hou houses ses the manuf manufac actur turin ing g faci facili lity ty for diffe differen rentt formulations of Beta Lactam range of antibiotics.

Unichem brings to the customer a blend of modern-day research and nearly six decades of rich experience experience in the Indian pharmaceuticals pharmaceuticals industry. The Company was promoted promoted by the late

Mr. Amrut Mody, a pioneer in the Indian pharmaceuticals pharmaceuticals

business.

Even though formulations account for a significant portion of Unichem's revenues, the Company Company also manufact manufactures ures active active pharmac pharmaceuti eutical cal ingredi ingredients ents (API (API or bulk actives). The Company has prudently addressed relevant and growing therapeutic areas like gastro-intestinal gastro-intestinal,, cardiovasculars, cardiovasculars, diabetes, psychaitry, psychaitry, neurology, anti bacterials, anti-infectives and pain management, among others.

Unichem is headquartered in Mumbai with five manufacturing locations in Roha (Maharashtra), Goa, Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh) and















approved by UK MHRA and MCC (South Africa). The Company has received ISO 9001:2000 for all its plants and corporate corporate office. Similarly Similarly the Company has received ISO14001:1996 certificates for its formulation plants ( Goa, Ghaziabad and Baddi) and Corporate Office at Mumbai.

As a future-focused future-focused initiative. Unichem has expanded its Research and Development facilit facility y in Jogeshwa Jogeshwari ri (Mumba (Mumbai) i) to spearhea spearhead d researc research h in Novel Novel Drug Drug Deliver Delivery y Systems (NDDS) and develop non-infringing routes for the manufacture of products directed at the regulated markets. The Company has also funded a collaborative research with the Indian Institute of Sciences, Bangalore. Unichem's growth strategy is fueled and backed by more than 2400 talented and motivated human resources.

Product manufactured in Baddi plant of UNICHEM LABS. LTD.:

Beta lactum antibodies



Ampillin and cloxacillin antibodies.



Ampoxin (injection, capsules,



Sulbacin injection.



Mymox capsules.



Myclave tablets.



Unienzyme tablets.

kid tabs,

neonate, & dry syrup)

















BADDI PLANT VIEW:-

Regulatory Approvals Approved by World Premier Regulatory Bodies - WHO, MCC - South Africa

•

and MHRA-UK.

Installed Capacity Dosage Form

Million/Annum/Per shift

Capsules

22 5

Vials

20

Tablet

48

Dry Syrup

06

















•

Unichem Specialities Division Launched

•

Acquisition of 100% stake in Niche Generics Limited, United Kingdom

2005 •

Set up of New Pharma Technology Development Center at GOA

•

Baddi Unit II plant was commissioned

•

Unichem acquired API manufacturing unit at Pithampur

2004 Restructuring of Unisearch & Launch of Unisearch CD Division

•

2002-2003 Animal Healthcare division divested

•

•

Subsidiaries in South Africa & Brazil established

•

Modernization of Ghaziabad formulations plant

2002 •

Established Joint Venture in UK called Niche Generics Limited

2001 •

New R&D Centre set up at Mumbai.

•

New Biosciences R&D Centre set up at Bangalore for research work in Biotechnology

2000

















1999 •

Modern Multipurpose Bulk Drug plant set up at Roha

•

MOLECULAR GENERICS DIVN Launched

1998 •

Baddi formulations plant fully operational

1997 •

•

Goa formulations plant fully operational New Corporate office set up at Unichem Bhavan Jogeshwari, Mumbai.

1996 •

Merger of Unichem Exports Ltd. & Unisearch Ltd. with Unichem Laboratories Ltd

1994 •

Bonus Issue

•

First major capital infusion in the Company. Private Placement of shares @ Rs. 265 premium

1993 •

Right issue @ Rs.40/- per share

•

Restructuring & transformation of the company inline with future growth strategies

















•

Bonus Issue

















1984 •

UNISEARCH Ltd. set up in Collaboration with Upjohn

•

Unichem entered the anti-biotic segment - Ampoxin launched

1983

•

US FDA approval for Hydrochlorothiazide at Jogeshwari plant

•

Anti-TB - Isoniazid, Rifampicin introduced in white tablet form for the first time in India – Anticox

1979

•

NEFEDIFINE - Unichem first to get clearance from Drug Authorities

1978

•

Bonus Issue 1:4

•

Roha Bulk Drug Plant established (Backward Integration)

1976

Fine Chemicals unit at Roha was set up



















•

Unichem's Research Laboratory recognised for Phd work by Bombay University. Unichem's R&D Centre recognised by Department of Science & Technology

1972 •

Padma Bhushan awarded to Late Mr. Amrut Mody for his pioneering efforts in Indian Pharma Industry

1970 •

Backward Integration for manufacture of Anti-TB Drugs

1968 •

Ghaziabad formulations plant setup

1963 •

Tie up with Uni Sankyo - Co-Marketing formulations

1962 •

Foreign Collaboration with UCB for bulk-drugs



















ORGANISATIONAL CHART





































ORGANISATIONAL CHART OF PANNNISSERY UNIT



















Dr. Prakash Amrut Mody

Dr. Dr. Prak Prakash ash Amrut Amrut Mod Mody y is a doctor doctorat atee in Organ Organic ic Medic Medicina inall Chem Chemist istry ry from from Unive Universi rsity ty of Bomb Bombay ay and and gradua graduate te alum alumni ni of Harva Harvard rd Busin Business ess Schoo School. l. He is associated with various industry associations. He serves on the Board of M/s. Kewal Kira Kiran n Clot Clothin hing g Limi Limited ted and on all Subsi Subsidia diary ry Comp Compani anies es of Unich Unichem em.. He was was appointed Chairman and Managing Director in 1999. He is the Chairman of the Management Committee of Unichem.

Mr. Bhoopendra Kumar Sharma

Mr. Bhoopendra Kumar Sharma holds a Masters degree in commerce from Agra Unive Universi rsity ty and a Postgr Postgradu aduate ate Diplo Diploma ma in Perso Personne nnell Manage Manageme ment nt from from Delh Delhii Unive Universi rsity ty.. He was was appoin appointed ted as our Ex Execu ecuti tive ve Dire Directo ctorr in 199 1994. 4. Prio Priorr to this this appointment he was Vice President in charge of operations and marketing since 1989. He joined the Company Company in 1969 and was in charge charge of operati operations ons of our Ghaziabad Ghaziabad plant till 1989.He serves on the Board of all Subsidiary Companies of Unichem. He has served on the Board of Unichem since 1994. He is a member of the Management Committee and Shareholders Grievance Committee of Unichem.





















Mr. Ramdas M Gandhi is an advocate and solicitor by profession. He holds a Masters degree in law from University of Bombay. He was enrolled as an attorney at law in the High Court of Mumbai in 1956. He also served as partner in a leading law firm in India India name namely ly M/s. M/s. Bhai Bhaisha shanke nkerr Kanga Kanga & Girdh Girdhar arla lal, l, and of M/s. M/s. Manil Manilal al Kher Kher Ambalal & Co. He presently serves as director in Pidilite Industries Limited, Aarti Industries Limited, Vinyl (India) Chemicals Limited and Aarti Drugs Limited. He has served on the Board of Unichem since 1985. He is the Chairman of the Shareholders Grievance Committee and member of Audit Committee, Compensation Committee and Management Committee of Unichem.

Mr. Nasser Munjee

Mr. Nasser Munjee holds a bachelor degree in economics from the London School of economics, a master of economic degree from the London School of economics.





















Mr. Anand Y Mahajan

Mr. Anand Y Mahajan is the Managing Director of Grindwell Norton Limited and the General Delegate of Compagnie de Saint-Gobain responsible for India, Sri-Lanka and Bangladesh. He has served on the Board of Unichem since 2005.





















VISION "To be a globa globall Pharm Pharmac aceut eutic ical al compa company ny with with increa increasin sing g focus focus on innov innovat ative ive research and developed markets"

MISSION "To be a caring Pharmaceutical company helping to enhance health through quality products"

OBJECTIVES OF THE COMPANY 1.

To setup and carry carry out research research and development development for the manufacture manufacture and development of antiseptic soaps, toothpastes, tooth powder etc... etc...





















PRODUCT PROFILE:1. Active Pharmaceutical Ingredients

Sr.

Current Product List

Therapeutic uses

1

Amlodipine Besylate

Anti Hypertensive

2

Amlodipine Maleate

Anti Hypertensive

3

Bendroflumethiazide

Anti Hypertensive, Diuretic

4

Bisoprolol Hemifumarate

B-Blocker

5

Brimonidine Tartrate

Anti Glucoma

6

Buprenorphine

Post Operative Analgesic

No.

Hydrochloride





















Sr. Prod Produc uctt Lis Listt

Ther Th erap apeu euti ticc use usess

No.

1

Aripiprazole

Antipsychotic

2

Eprosartan

Anti Hypertensive

Mesylate 3

Escitalopram

Anti Depressant

4

Lamotrigine

Anti Epileptic

5

Levetiracetam Anticonvulsant

6

Losartan

Anti Hypertensive

Potassium 7

Pantoprazole

Anti Ulcerative

Sodium 8

Rosuvastatin

HMG-CoA Re Reductase In Inhibitor

9

Zafirlukast

Anti As Asthmatic























Veterinary Products:-

Having been deeply imbibed with the philosophy of quality and reliability, Agvet Unichem has been the first to introduce many revolutionary veterinary products. The division has the most unique range of veterinary products that encompasses many facts of ailments and treatments.

Duraprogen*























A unique combination of two powerful antimicrobials against anaerobic and aerobic micro organisms and protozoa.

UNIMIX*























3.1 DEPARTMENTS/FUNCTIONAL AREAS:























MANUFACTURING DEPARTMENT:DEPARTMENT:-

Quality assurance Department A separate quality assurance department is functioning in this unit to ensure that all the products meet the required quality. The quality assurance dept. is entr entrust usted ed with with the the respo respons nsibi ibilit lity y of prep prepar arin ing g qu quali ality ty contr control ol plan planss and























PURCHASE DEPARTMENT

The purchase department is responsible for the continuous availability of raw material to the production department. The production department should see that all the required materials are purchased at the right time in the right quantity at the right price. Continuous availability of all the raw material are

























RESEARCH & DEVELOPMENT

























STORES DEPARTMENT

























MAINTENANCE DEPARTMENT

























Composition:-

























& L ti

id B ill

6 0 X 10 6









































































































































































































































































































































































Unichem Final Project Report

Recommend Documents